Vanguard Group Inc. Has $51.13 Million Position in Liquidia Technologies, Inc. $LQDA

Vanguard Group Inc. lessened its holdings in Liquidia Technologies, Inc. (NASDAQ:LQDA) by 2.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,466,640 shares of the company’s stock after selling 90,656 shares during the period. Vanguard Group Inc. owned 4.06% of Liquidia Technologies worth $51,133,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of LQDA. Hurley Capital LLC acquired a new stake in shares of Liquidia Technologies in the 1st quarter valued at $32,000. GAMMA Investing LLC lifted its position in Liquidia Technologies by 65.6% during the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock worth $44,000 after acquiring an additional 1,173 shares during the last quarter. D. E. Shaw & Co. Inc. acquired a new position in Liquidia Technologies during the 4th quarter worth $142,000. Bayesian Capital Management LP acquired a new position in Liquidia Technologies during the 4th quarter worth $163,000. Finally, ProShare Advisors LLC lifted its position in Liquidia Technologies by 63.9% during the 4th quarter. ProShare Advisors LLC now owns 17,853 shares of the company’s stock worth $210,000 after acquiring an additional 6,960 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insiders Place Their Bets

In other Liquidia Technologies news, CEO Roger Jeffs sold 20,252 shares of the company’s stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $14.28, for a total transaction of $289,198.56. Following the sale, the chief executive officer directly owned 1,038,560 shares of the company’s stock, valued at approximately $14,830,636.80. This represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sarah Krepp sold 2,673 shares of the company’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $14.28, for a total transaction of $38,170.44. Following the sale, the insider directly owned 142,499 shares in the company, valued at $2,034,885.72. This represents a 1.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 90,277 shares of company stock valued at $1,469,392 over the last 90 days. Company insiders own 30.10% of the company’s stock.

Liquidia Technologies Stock Performance

NASDAQ:LQDA opened at $26.25 on Tuesday. The firm’s 50-day moving average is $17.76 and its 200-day moving average is $16.04. Liquidia Technologies, Inc. has a 52-week low of $8.75 and a 52-week high of $28.00. The company has a debt-to-equity ratio of 9.84, a quick ratio of 2.41 and a current ratio of 2.49. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -15.44 and a beta of 0.14.

Liquidia Technologies (NASDAQ:LQDA) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.06). The company had revenue of $8.84 million for the quarter, compared to the consensus estimate of $3.90 million. Liquidia Technologies had a negative return on equity of 232.96% and a negative net margin of 732.17%.The business’s revenue for the quarter was up 141.5% on a year-over-year basis. Equities research analysts anticipate that Liquidia Technologies, Inc. will post -1.51 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on LQDA shares. BTIG Research reissued a “buy” rating on shares of Liquidia Technologies in a research report on Tuesday, May 27th. Jefferies Financial Group started coverage on shares of Liquidia Technologies in a research report on Friday, August 15th. They set a “buy” rating and a $43.00 target price for the company. Bank of America cut their target price on shares of Liquidia Technologies from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, June 11th. Needham & Company LLC boosted their target price on shares of Liquidia Technologies from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, August 12th. Finally, Raymond James Financial boosted their target price on shares of Liquidia Technologies from $33.00 to $41.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $32.11.

Liquidia Technologies Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).